Last checked at 
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
----------
Colefax Group PLC - London-based interior designer - For the six months ended October 31, pretax profit increases 33% to GBP4.5 million from GBP3.4 million a year before, on revenue which grew 25% year-on-year to GBP46.1 million from GBP37.0 million. The growth was driven by favourable trading conditions, including a strong housing market and demand for home-related products. Resumes dividend payments by declaring an interim payout of 2.5p. Looking ahead, despite favourable trading conditions going into the second half of the year, the rate of growth is expected to slow as the economy returns to normal.
----------
Newmark Security PLC - electronic and physical security systems provider - For the six months ended October 31, pretax loss widens to GBP879,000 from GBP267,000 a year before, due to higher administrative expenses due to the non-repeating of cost saving initiatives the prior year, and the company gearing up for future activities. However, revenue grows 23% year-on-year to GBP9.7 million from GBP7.9 million, via growth from the US Human Capital Management business.
----------
Cambium Global Timberland Ltd - plantation forest owner - As at October 31, net asset value declines 8.6% to 9.1 pence from 9.9p at the end of April. Looking ahead, the company continues to consider the timing for the contemplated winding up of the company.
----------
Standard Life Private Equity Trust PLC - investor in private equity funds focused on Europe - For the year ended September 30, net asset value total return is 37.9%, outperforming the FTSE All-Share index, which returned 27.9%. As at September 30, NAV per share is 673.8 pence, up 35% from 501.0p the same date the year before. Declares a total dividend of 13.6 pence per share, up from 13.2p the year before.
----------
Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - For the year ended September 30, pretax loss widens to GBP21.4 million from GBP9.2 million the year before, due to more than doubled research & development costs at GBP24.4 million from GBP10.5 million. This was in spite of revenue growing 75% year-on-year to GBP10.0 million from GBP5.7 million, driven by milestone payments from its outlicensing agreement with AstraZeneca PLC and preclinical development services for Jazz Pharmaceuticals.
----------
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
